|
Subsequent Events - Additional Information (Detail) (USD $)
In Thousands, except Share data, unless otherwise specified |
1 Months Ended | 9 Months Ended | 12 Months Ended | 1 Months Ended | 0 Months Ended | 1 Months Ended | 12 Months Ended | 9 Months Ended | 0 Months Ended | 1 Months Ended | 0 Months Ended | 4 Months Ended | 1 Months Ended | 0 Months Ended | 1 Months Ended | 2 Months Ended | 0 Months Ended | 1 Months Ended | 0 Months Ended | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jul. 26, 2013
|
Sep. 30, 2013
|
Sep. 30, 2012
|
Dec. 31, 2012
|
Dec. 31, 2011
|
Aug. 13, 2013
|
Jan. 20, 2012
Ziopharm [Member]
|
Feb. 07, 2011
Ziopharm [Member]
|
Jan. 06, 2011
Ziopharm [Member]
|
Mar. 15, 2013
AquaBounty [Member]
|
Feb. 28, 2013
AquaBounty [Member]
|
Jan. 31, 2013
AquaBounty [Member]
|
Dec. 31, 2012
AquaBounty [Member]
|
Sep. 30, 2013
Series F Redeemable Convertible Preferred Stock [Member]
|
Feb. 14, 2013
AquaBounty ECC [Member]
|
Mar. 31, 2013
AmpliPhi ECC [Member]
Upfront and Milestone Payments [Member]
Upfront [Member]
|
Mar. 31, 2013
Genopaver ECC [Member]
Upfront and Milestone Payments [Member]
Upfront [Member]
|
Apr. 27, 2013
Soligenix ECC [Member]
Upfront and Milestone Payments [Member]
Upfront [Member]
|
Jul. 26, 2013
Subsequent Event [Member]
|
Apr. 30, 2013
Subsequent Event [Member]
|
Oct. 31, 2013
Subsequent Event [Member]
Fibrocell Science [Member]
|
Oct. 29, 2013
Subsequent Event [Member]
Ziopharm [Member]
|
Mar. 15, 2013
Subsequent Event [Member]
AquaBounty [Member]
|
Feb. 28, 2013
Subsequent Event [Member]
AquaBounty [Member]
|
Jan. 31, 2013
Subsequent Event [Member]
AquaBounty [Member]
|
Apr. 30, 2013
Subsequent Event [Member]
Series F Redeemable Convertible Preferred Stock [Member]
|
Apr. 30, 2013
Subsequent Event [Member]
Series F Redeemable Convertible Preferred Stock [Member]
Shareholder
|
Feb. 14, 2013
Subsequent Event [Member]
AquaBounty ECC [Member]
|
Mar. 31, 2013
Subsequent Event [Member]
AmpliPhi ECC [Member]
Upfront and Milestone Payments [Member]
Upfront [Member]
|
Mar. 31, 2013
Subsequent Event [Member]
Genopaver ECC [Member]
Upfront and Milestone Payments [Member]
Upfront [Member]
|
Apr. 27, 2013
Subsequent Event [Member]
Soligenix ECC [Member]
Upfront and Milestone Payments [Member]
Upfront [Member]
|
|
| Subsequent Event [Line Items] | |||||||||||||||||||||||||||||||
| Amount drawn on promissory note | $ 300 | $ 200 | $ 100 | $ 200 | $ 200 | $ 100 | $ 200 | ||||||||||||||||||||||||
| Royalty rate as a percentage of gross profit | 16.66% | 16.66% | |||||||||||||||||||||||||||||
| Proceeds from issuance of redeemable convertible preferred shares | 150,000 | 150,000 | |||||||||||||||||||||||||||||
| Payment of stock issuance costs | 3,148 | 11 | 16 | 2,675 | 3,100 | 1,800 | |||||||||||||||||||||||||
| Redeemable convertible preferred stock, stated value | $ 7.88 | ||||||||||||||||||||||||||||||
| Dividend rate per annum | 6.00% | ||||||||||||||||||||||||||||||
| Common stock, authorized | 200,000,000 | 160,000,000 | 155,000,000 | 200,000,000 | 185,000,000 | ||||||||||||||||||||||||||
| Number of shares acquired | 18,714,814 | 18,714,814 | |||||||||||||||||||||||||||||
| Amount from private subscription offering | 4,907 | 4,907 | |||||||||||||||||||||||||||||
| Aggregate percentage of ownership | 53.82% | 53.82% | |||||||||||||||||||||||||||||
| Promissory note repaid | 500 | 34 | 34 | 300 | 500 | 500 | |||||||||||||||||||||||||
| Collaborative arrangement consideration received, shares | 24,000,000 | 1,034,483 | 24,000,000 | 1,034,483 | |||||||||||||||||||||||||||
| Collaborative arrangement consideration received, value | 2,400 | 3,000 | 1,331 | 3,000 | |||||||||||||||||||||||||||
| Decrease In Equity Securities | $ (32,123) | ||||||||||||||||||||||||||||||
| Shareholders approved a reverse stock split description | 1-for-1.75 | 1-for-1.75 | |||||||||||||||||||||||||||||
| Shares of common stock purchased from collaborative partners | 1,923,075 | 1,910,000 | 2,426,235 | 2,439,024 | 2,857,143 | ||||||||||||||||||||||||||
| Price per share | $ 5.20 | $ 5.75 | $ 4.80 | $ 4.10 | $ 3.50 | ||||||||||||||||||||||||||